コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rgical modalities of stage II/III rectal and metastatic colorectal cancer.
2 d DNA damage response pathway alterations on metastatic colorectal cancer.
3 ave established efficacy in the treatment of metastatic colorectal cancer.
4 mtCa(2+) is a novel therapeutic approach in metastatic colorectal cancer.
5 discerned potentially druggable targets for metastatic colorectal cancer.
6 se of placebo in the third-line treatment of metastatic colorectal cancer.
7 bevacizumab in the second-line treatment of metastatic colorectal cancer.
8 a standard of care for previously untreated metastatic colorectal cancer.
9 ab [arm B]) for patients with KRAS wild-type metastatic colorectal cancer.
10 ost per QALY in the third-line management of metastatic colorectal cancer.
11 ailable addressing the use of bevacizumab in metastatic colorectal cancer.
12 ct on future directions for the treatment of metastatic colorectal cancer.
13 hemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer.
14 ng as potential treatments for HER2-positive metastatic colorectal cancer.
15 ith capecitabine to target chemoradiation to metastatic colorectal cancer.
16 actor), is standard first-line treatment for metastatic colorectal cancer.
17 id cultures of patient-derived xenografts of metastatic colorectal cancer.
18 ubjected to PVE before major hepatectomy for metastatic colorectal cancer.
19 ed widely for cancer treatment, particularly metastatic colorectal cancer.
20 for diagnostic and therapeutic assessment of metastatic colorectal cancer.
21 ften under-represented in clinical trials of metastatic colorectal cancer.
22 capecitabine alone in elderly patients with metastatic colorectal cancer.
23 -tolerated regimen for elderly patients with metastatic colorectal cancer.
24 n patients with untreated RAS wild-type (WT) metastatic colorectal cancer.
25 on, such as those with microsatellite-stable metastatic colorectal cancer.
26 nts who received anti-EGFR-based therapy for metastatic colorectal cancer.
27 l of treatment strategies for liver-confined metastatic colorectal cancer.
28 motherapy after resection of liver- confined metastatic colorectal cancer.
29 (PS) is a prognostic factor in patients with metastatic colorectal cancer.
30 th head and neck squamous cell carcinoma and metastatic colorectal cancer.
31 ad experienced treatment failure with FU for metastatic colorectal cancer.
32 ent predictor of PFS and OS in patients with metastatic colorectal cancer.
33 a relevant prognosis marker in patients with metastatic colorectal cancer.
34 ed of actively enrolling treatment trials in metastatic colorectal cancer.
35 ative" have been adopted in trial designs in metastatic colorectal cancer.
36 lus leucovorin (LV) in first-line therapy of metastatic colorectal cancer.
37 n invaluable in the staging of patients with metastatic colorectal cancer.
38 erred irinotecan-based regimen in first-line metastatic colorectal cancer.
39 cetuximab and bevacizumab, in patients with metastatic colorectal cancer.
40 ents with heavily pretreated, HER2-amplified metastatic colorectal cancer.
41 during colon carcinogenesis and particularly metastatic colorectal cancer.
42 otherapy in patients with previously treated metastatic colorectal cancer.
43 dy in combination with standard regimens for metastatic colorectal cancer.
44 been approved for treatment of patients with metastatic colorectal cancer.
45 can that predicts prognosis in patients with metastatic colorectal cancer.
46 py improves survival in previously untreated metastatic colorectal cancer.
47 plus oxaliplatin in patients with untreated metastatic colorectal cancer.
48 ents (78%) who received prior irinotecan for metastatic colorectal cancer.
49 FU/LV as the standard systemic approach for metastatic colorectal cancer.
50 trastuzumab in patients with HER2-amplified metastatic colorectal cancer.
51 bination with chemotherapy for patients with metastatic colorectal cancer.
52 plus leucovorin as first-line treatment for metastatic colorectal cancer.
53 enefit to patients with previously untreated metastatic colorectal cancer.
54 were used to isolate CTCs from patients with metastatic colorectal cancer.
55 improvement in survival among patients with metastatic colorectal cancer.
56 c lesions, and skin from three patients with metastatic colorectal cancer.
57 vector, with E1b deleted, for patients with metastatic colorectal cancer.
58 lity of life in patients with FU-refractory, metastatic colorectal cancer.
59 primary tumor samples from 219 patients with metastatic colorectal cancer.
60 or anti-permeability agent for patients with metastatic colorectal cancer.
61 eatment strategy for patients with untreated metastatic colorectal cancer.
62 rgeted prevention and therapy of primary and metastatic colorectal cancer.
63 fluorouracil (FU) treatment in patients with metastatic colorectal cancer.
64 rin (LV) versus FU/LV alone in patients with metastatic colorectal cancer.
65 plus chemotherapy as first-line therapy for metastatic colorectal cancer.
66 by either LV or interferon in patients with metastatic colorectal cancer.
67 d to assess atezolizumab plus cobimetinib in metastatic colorectal cancer.
68 n and reduced survival time of patients with metastatic colorectal cancer.
69 testinal mucosa and universally expressed by metastatic colorectal cancer.
70 ividual patients during initial treatment of metastatic colorectal cancer.
71 embolization for unresectable liver-dominant metastatic colorectal cancer.
72 rial of patients with relapsed or refractory metastatic colorectal cancer.
73 underwent multidetector CT of the liver for metastatic colorectal cancer.
74 ffective first-line chemotherapy regimen for metastatic colorectal cancer.
75 point inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.
76 ment, results in prognostic heterogeneity of metastatic colorectal cancer.
77 herapy in patients with previously untreated metastatic colorectal cancer.
78 pecially in those with metastatic sarcoma or metastatic colorectal cancer.
79 sites than in those with isolated peritoneal metastatic colorectal cancer.
80 ing lymphocytes obtained from a patient with metastatic colorectal cancer.
82 , compared with patients with non-peritoneal metastatic colorectal cancer (194 [9%] of 2230; p=0.028
83 (63 months), gallbladder cancer (47 months), metastatic colorectal cancer (40 months), and hepatocell
84 (87%) of 10 553 patients had non-peritoneal metastatic colorectal cancer (4385 with one site of meta
85 ne were studied independently: patients with metastatic colorectal cancer (72 lesions), non-small cel
86 nosis (1,642 patients, 91%); of these cases, metastatic colorectal cancer accounted for 62% (n = 1,02
88 y and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard t
89 been available for patients with progressive metastatic colorectal cancer after front-line treatment
90 activity in heavily pretreated patients with metastatic colorectal cancer, all with prior irinotecan
91 Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methyl
92 years or older with chemotherapy-refractory metastatic colorectal cancer, an Eastern Cooperative Onc
93 pproved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck
94 ts support a role for Akt2 overexpression in metastatic colorectal cancer and establish a mechanistic
95 zumab, improved the outcome in patients with metastatic colorectal cancer and increased the incidence
96 gress in prolonging life among patients with metastatic colorectal cancer and increasing cure rates a
97 at led to approval of bevacizumab for use in metastatic colorectal cancer and metastatic lung cancer
98 rectal cancer, and 1181 (11%) had peritoneal metastatic colorectal cancer and other organ involvement
99 ts with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary t
101 is is a common presentation in patients with metastatic colorectal cancer and the overall survival is
102 survival and response rates in patients with metastatic colorectal cancer and thus, validate VEGF pat
103 ), 194 (2%) patients had isolated peritoneal metastatic colorectal cancer, and 1181 (11%) had periton
104 uracil, and irinotecan were investigated for metastatic colorectal cancer, and 979254, in which survi
105 phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of
106 trol in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatme
107 FOLFOX6 in Patients With Previously Treated Metastatic Colorectal Cancer] and HORIZON III [Cediranib
109 y mortality after initiation of treatment of metastatic colorectal cancer are poorly understood.
110 FR are currently approved for the therapy of metastatic colorectal cancer (as well as other tumors),
111 Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluoro
112 years with unresectable locally advanced or metastatic colorectal cancer, baseline Eastern Cooperati
113 inical trials demonstrate that patients with metastatic colorectal cancer benefit from therapy with m
115 linical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of
116 ith chemotherapy in unselected patients with metastatic colorectal cancer cannot be recommended.
119 approach based on selection of highly liver metastatic colorectal cancer cells in vivo to determine
121 ningfully improves survival of patients with metastatic colorectal cancer compared with doublets + be
122 ient focus group (11 patients with early and metastatic colorectal cancer convened during a teleconfe
123 0 years and older with a recent diagnosis of metastatic colorectal cancer (CRC) about their preferenc
124 utation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated wit
126 e cases" of two-arm clinical trials, one for metastatic colorectal cancer (CRC) patients treated with
127 a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with
128 uperior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated wi
129 orouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall s
130 with chemotherapy (CTX) in patients who have metastatic colorectal cancer (CRC), an increase in wound
131 FU) and oxaliplatin are standard therapy for metastatic colorectal cancer (CRC), but the development
139 ed With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI
140 ed With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI
141 patients with liver-only and liver-dominant metastatic colorectal cancer did not improve overall sur
142 n patients with liver-dominant or liver-only metastatic colorectal cancer did not improve PFS at any
143 scape of systemic therapies for unresectable metastatic colorectal cancer during the current era of t
146 For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associate
147 has doubled the median overall survival for metastatic colorectal cancer from 10 to 20 months, and t
148 ng median overall survival for patients with metastatic colorectal cancer from less than 9 months wit
149 retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3
150 retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3
151 in the third-line setting for patients with metastatic colorectal cancer from the US payer perspecti
154 IRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in pat
155 ival of patients diagnosed with unresectable metastatic colorectal cancer has increased from approxim
156 on of risk scoring systems for patients with metastatic colorectal cancer has limited clinical value
157 h was recently approved for the treatment of metastatic colorectal cancer, has antiangiogenic propert
158 motherapy for the treatment of patients with metastatic colorectal cancer, has provided proof of prin
161 survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event
162 biopsies were obtained from 14 patients with metastatic colorectal cancer (i) to test the feasibility
163 umumab to mFOLFOXIRI in patients with RAS WT metastatic colorectal cancer improved the ORR and rate o
164 for the treatment of initially unresectable metastatic colorectal cancer in humans were included.
165 nib seems to have promising activity against metastatic colorectal cancer in patients who received pr
166 eucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease pr
168 strated that highly activated fibroblasts in metastatic colorectal cancer increase tissue stiffness a
169 ning regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional
171 the peripheral circulation of patients with metastatic colorectal cancer is associated with a shorte
172 n the basis of these data, tumor response in metastatic colorectal cancer is not a necessary factor f
174 ed phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable o
175 d regimens in the treatment of patients with metastatic colorectal cancer led to several multicenter
176 ) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MS
177 resent in approximately 40% of patients with metastatic colorectal cancer (mCRC) and may be associate
178 o comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing ca
179 ients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuxim
182 Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely une
183 rvival (PFS) in patients with wild-type KRAS metastatic colorectal cancer (mCRC) in studies 20050203
187 ajectories and their associations with PD in metastatic colorectal cancer (mCRC) patients during cons
188 PET/CT) in a large cohort of chemorefractory metastatic colorectal cancer (mCRC) patients treated wit
189 esults of prospective immunomonitoring of 25 metastatic colorectal cancer (mCRC) patients treated wit
192 erm outcome in patients with chemorefractory metastatic colorectal cancer (mCRC) receiving cetuximab.
193 d RAS gene mutation testing in patients with metastatic colorectal cancer (mCRC) to detect resistance
195 mes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevaciz
196 tometry in peripheral blood of patients with metastatic colorectal cancer (mCRC) treated with bevaciz
197 Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assign
198 ebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed a
199 have witnessed progress in the management of metastatic colorectal cancer (mCRC) with more effective
202 I trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during
203 monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical stu
205 al radiation therapy (SIRT) in patients with metastatic colorectal cancer (mCRC), when informed by ra
206 recent advances in the medical treatment of metastatic colorectal cancer (mCRC), which include irino
227 ts disease-free 10 years after resection for metastatic colorectal cancer or gallbladder cancer were
228 ovements have been made in the management of metastatic colorectal cancer over the last two decades.
229 ng preclinical and clinical activity against metastatic colorectal cancer, particularly in combinatio
230 ipheral blood samples were collected from 62 metastatic colorectal cancer patients and 30 metastatic
234 that irinotecan (CPT-11) extends survival in metastatic colorectal cancer patients when administered
235 this paper, we review the published work on metastatic colorectal cancer, pertaining to the role of
236 0.86-1.25, p=0.69) and those with peritoneal metastatic colorectal cancer plus one other site of meta
238 in a separate population of 63 patients with metastatic colorectal cancer receiving fluoropyrimidine
239 n an independent cohort of 339 patients with metastatic colorectal cancer receiving FOLFOX4 in the Fe
242 ts show that proteomic sequencing of matched metastatic colorectal cancer samples is feasible, with h
244 ecreased expression of TFAP2E in primary and metastatic colorectal-cancer specimens and cell lines.
245 ergoing elective, biopsy-proven, primary non-metastatic colorectal cancer surgery from 2009 to 2014 w
246 l was to evaluate gefitinib in patients with metastatic colorectal cancer that had progressed despite
248 tandard-care option for treatment-refractory metastatic colorectal cancer that increases median overa
250 ment options are available for patients with metastatic colorectal cancer that progresses after all a
251 h irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to trea
253 umab Plus FOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer]), the 20-mg dose met the p
255 patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant d
256 e more likely than those with non-peritoneal metastatic colorectal cancer to be women (565 [41%] of 1
257 of a protocol that assigns all patients with metastatic colorectal cancer to one of a number of paral
258 andomly assigned 508 patients with untreated metastatic colorectal cancer to receive either FOLFIRI p
259 an important determinant of the response of metastatic colorectal cancer to targeted treatments.
260 r intraarterial (90)Y-glass microspheres for metastatic colorectal cancer to the liver by comparing v
261 en, 12 women; age, 68 +/- 12 y [+/-SD]) with metastatic colorectal cancer to the liver, and tumor pro
264 ST) for response evaluation of patients with metastatic colorectal cancer treated with a combination
265 ll survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy p
267 n an application to real data collected from metastatic colorectal cancer tumors, more associations b
268 Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 t
269 ne 22, 2017, 57 patients with HER2-amplified metastatic colorectal cancer were enrolled in the MyPath
273 reviously untreated patients with measurable metastatic colorectal cancer were randomly assigned to o
275 with chemotherapy-refractory liver-dominant metastatic colorectal cancer were treated with (90)Y rad
276 enefit in patients with previously untreated metastatic colorectal cancer when combined with irinotec
277 of survival and progression in patients with metastatic colorectal cancer, whereas p53 and EGFR are n
278 tikinase inhibitor with survival benefits in metastatic colorectal cancer which has progressed after
279 tikinase inhibitor with survival benefits in metastatic colorectal cancer which has progressed after
280 omes among patients with locally advanced or metastatic colorectal cancer who achieve a complete resp
281 btained from the plasma of 503 patients with metastatic colorectal cancer who enrolled in the CORRECT
282 ation in patients with irinotecan-refractory metastatic colorectal cancer who had developed no or mil
283 erent two-drug combinations in patients with metastatic colorectal cancer who had not been treated pr
287 der with previously untreated, unresectable, metastatic colorectal cancer, who were not deemed to be
288 es in patients with unpretreated advanced or metastatic colorectal cancer, who were regarded as not p
289 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt c
290 s in the UK with newly diagnosed advanced or metastatic colorectal cancer whose tumour was wild-type
291 blished from tumor biopsies of patients with metastatic colorectal cancer with a success rate of 71%.
292 trium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases.
293 ory, histologically confirmed HER2-amplified metastatic colorectal cancer with measurable or evaluabl
294 patients with available data) and peritoneal metastatic colorectal cancer with other sites of metasta
295 ss the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and p
296 mpared the global gene expression profile of metastatic colorectal cancer with that of primary cancer
297 total of 779 FFPE samples from patients with metastatic colorectal cancer with valid NGS results were
299 overall survival compared with patients with metastatic colorectal cancer without peritoneal involvem